Lupin is currently trading at Rs. 1488.55, up by 4.85 points or 0.33% from its previous closing of Rs. 1483.70 on the BSE.
The scrip opened at Rs. 1495.90 and has touched a high and low of Rs. 1495.90 and Rs. 1477.70 respectively. So far 5222 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1911.55 on 09-Feb-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1,495.90 and Rs. 1,399.00 respectively. The current market cap of the company is Rs. 67376.78 crore.
The promoters holding in the company stood at 46.74%, while Institutions and Non-Institutions held 41.85% and 11.41% respectively.
Pharma Major Lupin has received tentative approval for its Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Kowa Company’s Livalo Tablets 1 mg, 2 mg and 4 mg. The filing is from company’s Pithampur (Indore) manufacturing facility.
The company’s Pitavastatin Tablets, 1 mg, 2 mg and 4 mg are the AB rated generic equivalent of Kowa's Livalo Tablets, 1 mg, 2 mg and 4 mg. Pitavastatin Tablets are indicated as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Livalo Tablets had US sales of $245.3 million as per IMS MAT Sep 2016.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
